Clinical Trial Update: A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002) [Phase 3]

View source ↗

Summary

Phase 3 study MK-6072 and MK-3415A in antibiotic-treated Clostridium difficile infection has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clostridium Difficile Infection

Drugs mentioned

• MK-3415A (null)
• MK-6072 (null)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Clostridium Difficile Infection | Phase 3 | Status: COMPLETED | Results posted: 2016-12-15